A well-done randomized trial was conducted in which 2,763 women with a history of coronary heart disease were randomly assigned in equal proportion to: a) A regimen of 0.625 mg/day of conjugated estrogens and 0.25 mg/day of medroxyprogestrone acetate; or b) A placebo. During an average follow-up of 4.1 years, the incidence of the combined endpoint, myocardial infarction and death from coronary heart disease, was identical in the two groups (relative risk = 0.99, 95% CI = 0.80-1.22). A critic of the study contended that the results may have been confounded, since diagnostic tests to ascertain the extent of coronary and other vascular disease at the outset of this trial were not performed on the study participants. Do you agree